Cargando…

COVID-19 Vaccine Effectiveness in Oncology Patients

Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients we...

Descripción completa

Detalles Bibliográficos
Autor principal: LA Costa, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214963/
https://www.ncbi.nlm.nih.gov/pubmed/35755900
http://dx.doi.org/10.6004/jadpro.2022.13.4.6
_version_ 1784731112476508160
author LA Costa, Rachel
author_facet LA Costa, Rachel
author_sort LA Costa, Rachel
collection PubMed
description Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients were not included in the initial COVID-19 vaccine trials. Will patients with cancer mount an adequate serologic response to vaccination to be protected from COVID-19 infection? Overall, oncology patients had diminished antibody response to the COVID-19 vaccines compared with healthy patients. The patients with the lowest seroconversion rates were those who received anti-CD20 monoclonal antibody therapy, Bruton tyrosine kinase inhibitor therapy, stem cell transplantation, and chimeric antigen receptor T-cell therapy. Although the response may not be robust, expert organizations strongly recommend that oncology patients should pursue COVID-19 vaccination and booster to ensure some degree of protection from infection. Immunocompromised patients should continue to practice mask wearing, social distancing, and proper hand hygiene to minimize the risk of contracting COVID-19.
format Online
Article
Text
id pubmed-9214963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-92149632022-06-23 COVID-19 Vaccine Effectiveness in Oncology Patients LA Costa, Rachel J Adv Pract Oncol Practice Matters Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients were not included in the initial COVID-19 vaccine trials. Will patients with cancer mount an adequate serologic response to vaccination to be protected from COVID-19 infection? Overall, oncology patients had diminished antibody response to the COVID-19 vaccines compared with healthy patients. The patients with the lowest seroconversion rates were those who received anti-CD20 monoclonal antibody therapy, Bruton tyrosine kinase inhibitor therapy, stem cell transplantation, and chimeric antigen receptor T-cell therapy. Although the response may not be robust, expert organizations strongly recommend that oncology patients should pursue COVID-19 vaccination and booster to ensure some degree of protection from infection. Immunocompromised patients should continue to practice mask wearing, social distancing, and proper hand hygiene to minimize the risk of contracting COVID-19. Harborside Press LLC 2022-05 2022-06-21 /pmc/articles/PMC9214963/ /pubmed/35755900 http://dx.doi.org/10.6004/jadpro.2022.13.4.6 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Practice Matters
LA Costa, Rachel
COVID-19 Vaccine Effectiveness in Oncology Patients
title COVID-19 Vaccine Effectiveness in Oncology Patients
title_full COVID-19 Vaccine Effectiveness in Oncology Patients
title_fullStr COVID-19 Vaccine Effectiveness in Oncology Patients
title_full_unstemmed COVID-19 Vaccine Effectiveness in Oncology Patients
title_short COVID-19 Vaccine Effectiveness in Oncology Patients
title_sort covid-19 vaccine effectiveness in oncology patients
topic Practice Matters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214963/
https://www.ncbi.nlm.nih.gov/pubmed/35755900
http://dx.doi.org/10.6004/jadpro.2022.13.4.6
work_keys_str_mv AT lacostarachel covid19vaccineeffectivenessinoncologypatients